Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

References

• Eckel RH Grundy SM Zimmet PZ The metabolic syndrome Lancet 2005 365 9468 1415 1428 15836891
   PubMed Web of Science ®Google Scholar
• O’Neill S O’Driscoll L Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies Obes Rev 2015 16 1 1 12
   PubMed Web of Science ®Google Scholar
• Aguilar M Bhuket T Torres S Liu B Wong RJ Prevalence of the metabolic syndrome in the United States, 2003–2012 JAMA 2015 313 19 1973 1974 25988468
   PubMed Web of Science ®Google Scholar
• van Vliet-Ostaptchouk JV Nuotio ML Slagter SN The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies BMC Endocr Disord 2014 14 9 24484869
   PubMed Web of Science ®Google Scholar
• Rosenthal N Meininger G Ways K Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus Ann N Y Acad Sci 2015 1358 1 28 43 26305874
   PubMed Web of Science ®Google Scholar
• Stenlöf K Cefalu WT Kim KA Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 2013 15 4 372 382 23279307
   PubMed Web of Science ®Google Scholar
• Stenlöf K Cefalu WT Kim KA Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study Curr Med Res Opin 2014 30 2 163 175 24073995
   PubMed Web of Science ®Google Scholar
• Lavalle-González FJ Januszewicz A Davidson J Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Diabetologia 2013 56 12 2582 2592 24026211
   PubMed Web of Science ®Google Scholar
• Wilding JP Charpentier G Hollander P Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 2013 67 12 1267 1282 24118688
   PubMed Web of Science ®Google Scholar
• Forst T Guthrie R Goldenberg R Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Diabetes Obes Metab 2014 16 5 467 477 24528605
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V de Zeeuw D Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes Diabetes Care 2015 38 3 403 411 25468945
   PubMed Web of Science ®Google Scholar
• Fulcher G Matthews DR Perkovic V Efficacy and safety of canagliflozin used in conjunction with sulfonylurea in patients with type 2 diabetes mellitus: a randomized, controlled trial Diabetes Ther 2015 6 3 289 302 26081793
   PubMed Web of Science ®Google Scholar
• Fulcher G Matthews DR Perkovic V Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes Diabetes Obes Metab 2016 18 1 82 91 26450639
   PubMed Web of Science ®Google Scholar
• Rosenstock J Chuck L Gonzalez-Ortiz M Merton K Craig J Capuano G Initial combination therapy with canagliflozin plus metformin versus each component as monotherapy in drug-naive type 2 diabetes Diabetes Care 2016 39 3 353 362 26786577
   PubMed Web of Science ®Google Scholar
• Rodbard HW Seufert J Aggarwal N Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin Diabetes Obes Metab 2016 18 8 812 819 27160639
   PubMed Web of Science ®Google Scholar
• Yale JF Bakris G Cariou B Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Diabetes Obes Metab 2013 15 5 463 473 23464594
   PubMed Web of Science ®Google Scholar
• Yale JF Bakris G Cariou B Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease Diabetes Obes Metab 2014 16 10 1016 1027 24965700
   PubMed Web of Science ®Google Scholar
• Bode B Stenlöf K Sullivan D Fung A Usiskin K Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial Hosp Pract 2013 41 2 72 84
   PubMedGoogle Scholar
• Bode B Stenlöf K Harris S Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes Diabetes Obes Metab 2015 17 3 294 303 25495720
   PubMed Web of Science ®Google Scholar
• Cefalu WT Leiter LA Yoon KH Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Lancet 2013 382 9896 941 950 23850055
   PubMed Web of Science ®Google Scholar
• Leiter LA Yoon KH Arias P Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study Diabetes Care 2015 38 3 355 364 25205142
   PubMed Web of Science ®Google Scholar
• Schernthaner G Gross JL Rosenstock J Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial Diabetes Care 2013 36 9 2508 2515 23564919
   PubMed Web of Science ®Google Scholar
• Ji L Han P Liu Y Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea Diabetes Obes Metab 2015 17 1 23 31
   PubMed Web of Science ®Google Scholar
• Lavalle-González FJ Eliaschewitz FG Cerdas S Del Pilar CM Tong C Alba M Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America Curr Med Res Opin 2016 32 3 427 439 26579834
   PubMed Web of Science ®Google Scholar
• Mudaliar S Polidori D Zambrowicz B Henry RR Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside Diabetes Care 2015 38 12 2344 2353 26604280
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2015 38 1 140 149 25538310
   PubMed Web of Science ®Google Scholar
• Sinclair A Bode B Harris S Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies BMC Endocr Disord 2014 14 1 37 24742013
   PubMed Web of Science ®Google Scholar
• Sinclair AJ Bode B Harris S Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis J Am Geriatr Soc 2016 64 3 543 552 27000327
   PubMed Web of Science ®Google Scholar
• Gilbert RE Weir MW Fioretto P Impact of age and estimated glomerular filtration rate on the glycaemic efficacy and safety of canagliflozin: a pooled analysis of clinical studies Can J Diabetes 2016 40 3 247 257 27052454
   PubMed Web of Science ®Google Scholar
• Gavin JR3rd Davies MJ Davies M Vijapurkar U Alba M Meininger G The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus Curr Med Res Opin 2015 31 9 1693 1702 26121561
   PubMed Web of Science ®Google Scholar
• Davidson JA Aguilar R Lavalle González FJ Efficacy and safety of canagliflozin in type 2 diabetes patients of different ethnicity Ethn Dis 2016 26 2 221 228 27103773
   PubMed Web of Science ®Google Scholar
• Wilding JPH Blonde L Leiter LA Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus J Diabetes Complications 2015 29 3 438 444 25660137
   PubMed Web of Science ®Google Scholar
• Rahman A Kittikulsuth W Fujisawa Y Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome J Hypertens 2016 34 5 893 906 26982381
   PubMed Web of Science ®Google Scholar
• Tahara A Kurosaki E Yokono M Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice Eur J Pharmacol 2013 715 1–3 246 255 23707905
   PubMed Web of Science ®Google Scholar
• Thomas L Grempler R Eckhardt M Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats Diabetes Obes Metab 2012 14 1 94 96 21985693
   PubMed Web of Science ®Google Scholar
• Matfin G Challenges in developing therapies for the metabolic syndrome Br J Diabetes Vasc Dis 2007 7 4 152 156
   Google Scholar
• Zinman B Wanner C Lachin JM Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar